Table 2.
Gene Therapies Products Candidates Under Clinical Trial
| Drug Name | Manufacturer | Indication | Phase | Vector (Delivery Mode) |
|---|---|---|---|---|
| NSR-REP1 | Nightstar Therapeutics | Choroideremia | 2 | AAV (in vivo) |
| DNX-2401 | DNAtrix | Glioblastoma/gliosarcoma | 2 | Adenovirus (in vivo) |
| ONCOS-102 | Targovax | Mesothelioma | 1/2 | Adenovirus (in vivo) |
| Ofranergene obadenovec (VB-111) | VBL Therapeutics | Glioblastoma | 3 | Adenovirus (in vivo) |
| Sepravir | Virtuu | Mesothelioma | 1/2 | Herpesvirus (in vivo) |
| Pexastimogene devacirepvec (Pexa-Vec) | SillaJen | Hepatocellular carcinoma | 3 | Vaccinia (in vivo) |
| Vocimagene amiretrorepvec (Toca 511) | Tocagen | Glioma | 3 | Retrovirus (ex vivo) |